STUDY QUESTION: Do PATL2 mutations account for female infertility with oocyte germinal vesicle (GV) arrest?
Introduction
Approximately 15% of couples are affected by infertility (Gurunath et al., 2011) . With the advent of IVF and ICSI, most infertile couples eventually have their own babies. However, recurrent IVF or ICSI failure still occurs in some cases such as oocyte maturation arrest for which therapeutic approaches are currently unavailable. Oocyte maturation arrest is an extremely rare syndrome causing primary female infertility, characterized by repeated production of a majority of immature oocytes or entirely immature oocytes (Beall et al., 2010) . Although numerous mouse models have linked several genes with the phenotype of oocyte maturation arrest (Fan et al., 2009; Mehlmann et al., 2002 Mehlmann et al., , 2004 Park et al., 2004; Zhang et al., 2010) , the genetic etiology of this phenotype in humans remains largely unknown.
Recently, it was demonstrated that TUBB8 (tubulin beta 8 class VIII) mutations are responsible for oocyte maturation arrest at metaphase I (MI) stage (Huang et al., 2017; Chen et al., 2017a; Feng et al., 2016a,b) . We showed that TUBB8 mutations account for around 30% of the individuals affected with the condition (Huang et al., 2017) . Two independent studies have recently demonstrated that infertility in some women with oocyte germinal vesicle (GV) arrest was caused by biallelic mutations in PATL2 (Maddirevula et al., 2017; Chen et al., 2017b) . PATL2 encodes an RNA-binding protein (mRNP) that was initially regarded as a translational repressor. It was demonstrated that overexpression of PATL2 ortholog (labeled P100) in Xenopus oocytes represses mRNA translation and blocks oocyte meiosis I progression (Nakamura et al., 2010) . Intriguingly, loss-of-function mutations of PATL2 in humans result in oocyte GV arrest instead of triggering GV breakdown (GVBD) (Maddirevula et al., 2017; Chen et al., 2017b) . The exact pathogenic mechanism by which mutations of PATL2 cause human oocyte maturation arrest is as yet unknown.
We analyzed a cohort of nine unrelated primary infertile females with oocyte GV arrest in order to assess the involvement of PATL2. We identified five novel point mutations and one recurrent splicing mutation in PATL2 in four of nine (44.4%) unrelated patients, indicating an unexpectedly high prevalence of PATL2 mutational events in oocyte GV arrest. These new findings suggest that PATL2 mutations are the main cause of oocyte GV arrest in this group of Chinese patients and indicate a prognostic value of testing for PATL2 mutations in primary infertile women with oocyte GV arrest.
Materials and Methods

Patients
Nine unrelated primary infertile females presenting with oocyte GV arrest were recruited from the Center for Reproductive Medicine, Anhui Provincial Hospital. All women had a normal karyotype (46, XX). Genomic DNA samples were prepared from all nine affected individuals and all their available family members. Written informed consent was obtained from every participant. All studies on human subjects were approved by the biomedical research ethics committee of Anhui Medical University.
Sequence analysis of PATL2
Genomic DNA was extracted from peripheral blood samples using the QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's protocol. All the coding regions of PATL2 were amplified by PCR using the primers shown in Table I . The PCR products underwent direct Sanger sequencing in both forward and reverse directions, using an ABI 3100 DNA analyzer (Applied Biosystem, Foster City, CA, USA). Exome Aggregation Consortium (ExAC) Browser (http://exac.broadinstitute. org/) and Genome Aggregation Database (gnomAD) Browser Beta (http://gnomad.broadinstitute.org/) were used to search the allele frequencies of the variants. Conservation among species of the affected amino acid residues was analyzed through multiple sequence alignment of the human PATL2 protein with its paralog and orthologs using MultiAlin (http:// multalin.toulouse.inra.fr/multalin/multalin.html). The pathogenicity of the identified variants on PATL2 protein was assessed using the scale-invariant 
Molecular modeling
PATL2 mutations were mapped using PyMOL onto the atomic model of the C-terminal domain of PATL2 (residues 299-540) based on the 34% identical C-terminal domain of PAT1 (PDB: 2XEQ; Modeling QMEAN score of -2.79).
Evaluation of oocyte phenotypes
Before ICSI was carried out, morphological analysis was performed to evaluate the degree of oocyte maturity under a light microscope. Oocytes at metaphase II (MII) stage, with the first polar body extruded (Fig. 1) , were regarded to be mature and were selected for ICSI. Oocytes with an intact nucleus (called GV) were at the GV stage. Oocytes that contained no GV or polar body were at metaphase I (MI) stage (Fig. 1) . GV oocytes and MI oocytes were considered to be immature and underwent IVM.
Results
Mutations of PATL2 in our cohort
Four of the nine genetically independent patients carried biallelic PATL2 mutations. The first patient (F1: II-1), one of two affected sisters descending from a consanguineous family, was found to be homozygous for a missense mutation NM_001145112.1 (PATL2): c.1127G>A
(p.R376Q) (Fig. 2) . Her sister (F1: II-2), 30 years old, was also affected by primary infertility due to oocyte GV arrest and carried the same homozygous mutation. The twin brother of F1: II-2, homozygous for this mutation, was fertile. Their consanguineous parents were both heterozygous for the mutation. The second patient (F2: II-1) had no history of consanguinity. She carried compound heterozygous mutations consisting of a recurrent splicing mutation c.223-14_223-2delCCCTCCTGTTCCA (eventually causing a frameshift and introducing a premature stop codon (PTC) p.R75Vfs*21) (Chen et al., 2017b) and a novel splicing mutation c.1225-2A>G. These two mutations were inherited from her parents. Her sister (F2: II-2) had a 2-year history of primary infertility and planned to undergo IVF treatment. She carried a heterozygous mutation c. 1225-2A>G. The third patient (F3: II-1), with no history of consanguinity, had compound heterozygous nonsense mutations: c.1282G>T (p.E428*) inherited from her father and c.1300C>T (p.Q434*) inherited from her mother. Her sister (F3: II-2) also had a 3-year history of primary infertility and had undergone three failed IUI cycles. She was heterozygous for the mutation p.Q434*. The fourth patient (F4: II-3), carried compound heterozygous mutations: a nonsense mutation c.1282G>T (p.E428*) and a frameshift mutation c.865delA (p.T289Lfs*6). Her two elder sisters (F4: II-1 and F4: II-2, 42 and 38 years of age, respectively) had experienced repeated IVF/ICSI failures due to oocyte maturation arrest. Both of them carried the same compound heterozygous mutations. Their father was heterozygous for p.E428* and their mother was heterozygous for p.T289Lfs*6. No mutations in PATL2 were identified in the remaining five patients (Fig. 2) . The missense mutation p.R376Q was found at a low allele frequency of 1/18310 in the ExAC browser but the other four mutations were not found (Table II) . In addition, the recurrent splicing mutation c. 223-14_223-2delCCCTCCTGTTCCA (p.R75Vfs*21) had an allele frequency of 1/18028.
The amino acid in position p.R376 is highly conserved based on analysis with MultiAlin and the missense mutation p.R376Q was predicted to be damaging to the function of the PATL2 protein, by SIFT, Polyphen and MutationTaster (Table II) . The nonsense mutations p.E428* and p.Q434* and the frameshift mutation p.T289Lfs*6 were predicted to introduce a PTC in the mRNA of PATL2. The splicing mutation c.1225-2A>G was predicted to abolish the canonical splice acceptor site of exon 13 by NNsplice, which may lead to exon 13 being skipped in the mRNA and resulting in a 47-amino-acid in-frame deletion (p.409_455del), affecting the PAT1 domain at the C-terminus of the protein. Another possible consequence of this mutation is that a cryptic acceptor splice site (109 bp downstream of the wild-type site) might be activated, resulting in a frameshift and the introduction of a PTC (p.A409Sfs*21). The recurrent splicing mutation c. 223-14_223-2delCCCTCCTGTTCCA (p.R75Vfs*21) was previously shown to cause a frameshift and introduce a PTC (Chen et al., 2017b) .
Prediction of the effects of the mutations on protein conformation
The residue R376 together with nearby residues K369, L316, F312, E309, E319 and L305 (corresponding to residues R599, L534, Y530, E527, E537 and L523, respectively, in PATL1) constitute a highly conserved domain (Fig. 3A) (Braun et al., 2010) . Notably, a salt bridge may exist between the guanidine group of R376 and the carboxyl group of E319 (Fig. 3B) . The mutation of p.R376Q may destabilize the local environment by not only breaking the salt bridge ( Figure 3B ) between these residues but also decreasing the positive charge in that conserved domain, which possibly affects RNA binding.
If the splicing mutation c.1225-2A>G leads to skipping of exon 13, this would result in a 47-residue deletion (p.409_455del) located in the middle of the folded domain (marked pink in Fig. 3A) . Removal of that fragment is predicted to disrupt protein folding and consequently affect protein function.
Clinical characteristics and phenotypes of oocytes with mutations in PATL2
All of the nine unrelated patients with primary infertility had recurrent early rescue ICSI or ICSI failure. In each of these patients, all the collected oocytes were immature and consistently remained at GV stage, even after IVM, and none of these oocytes were selected for ICSI. The clinical characteristics of the oocytes retrieved from patients are summarized in Table III . No obvious morphological differences were observed between the oocytes collected from the patients in this study, regardless of PATL2 mutation status.
Discussion
In total, four of nine (44.4%) unrelated affected individuals were diagnosed genetically with biallelic PATL2 mutations. A previous study showed that five of 180 (2.78%) infertile women, most of whose oocytes failed to mature after repeated IVF and ICSI attempts, were identified with biallelic PATL2 mutations (Chen et al., 2017b) . Compared with these previous data, our data may indicate an unexpectedly high prevalence of PATL2 mutations in infertile women with oocyte GV arrest. This may be related to a bias in patient recruitment or the limited number of patients involved in this study. However, we consider it most important that all the retrieved oocytes from our patients were immature and consistently arrested at GV stage, even after IVM. Patients that had a majority of GV oocytes with a small portion of MI oocytes, or MII oocytes, or oocytes even fertilized but arrested at an early stage of embryo development, were not analyzed in this study, although previous studies showed that some patients with PATL2 mutations could have slight phenotypic variabilities (Maddirevula et al., 2017; Chen et al., 2017b) .
Five novel point mutations and one recurrent splicing mutation in PATL2 were identified in this study (Fig. 3C) , which further expand the mutation spectrum of PATL2. Among them, two nonsense mutations (p.E428* and p.Q434*), one frameshift mutation (p.T289Lfs*6) and the recurrent splicing mutation (p.R75Vfs*21) have a PTC in the mRNA. These PTC mutations were predicted to trigger rapid degradation of the corresponding aberrant mRNAs through the non-sense mediated mRNA decay pathway, resulting in no production of the protein (Mendell et al., 2004) . Even if the aberrant mRNAs were not degraded, the truncated protein produced, lacking a large fragment in the RNA-binding domain, would not be functional. The missense mutation p.R376Q was predicted to be damaging by in silico methods. The highly conserved, positively charged residue R376 is a critical component of a highly conserved region on the surface of the PAT1 domain (Fig. 2) (Braun et al., 2010) . In addition, a salt bridge may exist between the residues R376 and E319, which may contribute to the conformation of that region on the surface of the PAT1 domain. The mutation p.R376Q may break the salt bridge, decrease the positive charge in the region, and impair the conformation of the PAT1 domain, finally resulting in loss of the RNA-binding ability. The splicing mutation c.1225-2A>G was predicted to abolish the canonical splice acceptor site of exon 13. This mutation may cause exon 13 to be skipped in the mRNA and lead to a 47-amino-acid in-frame deletion (p.409_455del) in the PAT1 domain of the PATL2 protein, resulting in loss of function of the protein. Alternatively, this mutation may cause the activation of a cryptic splice acceptor (109 bp downstream of the mutation), resulting in a frameshift and the introduction of a PTC (p. A409Sfs*21). Either way, the mutation c.1225-2A>G is predicted to cause severe loss-of-function of PATL2. RT-PCR and immunostaining analysis using the oocytes from the affected individuals may help to evaluate the possible effects of the novel mutations on the mRNA and the protein. However, no oocytes were available for such analyses in the present study.
It has been proposed that different mutations in PATL2 may have different types of phenotypic effect (Chen et al., 2017b) study showed that some missense mutations may cause less impairment to the function of PATL2 and the affected individuals can have a small number of MI oocytes, or oocytes with first polar body extruded (PB1 oocytes). These PB1 oocytes either failed to be fertilized or were fertilized but arrested at an early stage of embryo development (Chen et al., 2017b) . However, in the present study, no obvious differences were observed between the oocytes with biallelic missense mutations and that with biallelic loss-of-function mutations. This may be because residue R376 plays a critical role in the function of the protein, and the missense mutation p.R376Q may have the same effect as loss-offunction mutations. All four affected individuals with PATL2 mutations declared no other medical impairment apart from the primary infertility. In addition, one male (F1: II-3) with a homozygous missense mutation p.R376Q was fertile. It has been proposed that the effects of PATL2 mutations are limited to females (Maddirevula et al., 2017) . In fact, these clinical manifestations concur perfectly with the fact that PATL2 is highly expressed in immature oocytes (Maddirevula et al., 2017; Chen et al., 2017b; Nakamura et al., 2010) . Specifically, PATL2 is highly abundant in the cytoplasm of GV oocytes but declines precipitously with the onset of GVBD. It has been shown that overexpression of the PATL2 ortholog (P100) in Xenopus oocytes results in the arrest of oocytes before GVBD. As in previous studies, our study also showed that lossof-function mutations of PATL2 in humans cause oocyte GV arrest. These results showed that either up-regulation or down-regulation of PATL2 expression would not promote the occurrence of GVBD. Further work is needed to explore the different pathways of up-and down-regulation of PATL2 and their corresponding roles in the pathogenic mechanism(s) responsible for oocyte GV arrest.
Those female carriers (F2: II-2 and F3: II-2) who have one of the biallelic mutations in the proband of their family suffer primary infertility and are planning for IVF/ICSI treatment. Their mothers also carry one of the biallelic mutations but are fertile. Generally, the diagnosis of oocyte maturation arrest is defined during IVF/ICSI treatment. Thus, co-segregation analysis of phenotype and genotype in these two families (F2 and F3) did not include these individuals whose phenotype is not defined yet (in this study phenotype is considered as oocyte GV arrest rather than primary infertility). Given that these two females have their genotypes of PALT2 before IVF/ICSI treatment, and given that it appears more likely that they have different causes of infertility from the proband of their family, it is highly possible that they will have a normal proportion of mature oocytes in their IVF or ICSI treatment. In the general population, males with biallelic homozygous/heterozygous mutations, or female carriers with a heterozygous mutation of PATL2 are fertile and can transmit the mutation to their offspring. This could be one of the underlying factors for the unexpected high proportion of PATL2 mutations in primary infertile women with oocyte GV arrest.
In our cohort 55.6% of affected individuals with oocyte GV arrest had no mutations in the coding region of PATL2. Other mutations located in the intronic or promoter region of PATL2, or probably PATL2 duplications (with an effect resembling the over-expression of PATL2), could not be excluded. Alternatively, other unknown causative genes could be implicated in this condition.
Current strategies to improve the outcome of some cases that have the occasional production of immature oocytes include dual trigger with GnRH agonist and HCG (Griffin et al., 2014) , delaying the oocyte maturation trigger by 1 day (Vandekerckhove et al., 2014) , a lag time between ovulation trigger and oocyte aspiration (Weiss et al., 2014) , and use of IVM (Hourvitz et al., 2010) . However, at present these strategies do not overcome the syndrome of oocyte maturation arrest. A molecular diagnosis, through testing for PATL2 mutations, could save an affected female and her family from the financial and emotional hardship of repeated failed cycles. The use of donor eggs or adoption could be options for these couples that want a baby. Further work is also needed to explore a new, advanced IVM protocol, which my help to overcome this condition in the future.
In conclusion, this study confirms previous findings that PATL2 is required for human oocyte maturation and female fertility, and also indicates the potential prognostic value of testing for PATL2 mutations in infertile women with oocyte GV arrest.
